| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/16/2002 | WO2001066100A3 Pharmaceutical composition |
| 05/16/2002 | WO2001049654A3 Substituted aminomethyl-phenyl-cyclohexane derivatives |
| 05/16/2002 | WO2001047928A3 Imidazo 1,3,5 triazinones and the use thereof |
| 05/16/2002 | WO2001045663A3 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
| 05/16/2002 | WO2001040521A3 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/16/2002 | WO2001039747A3 Cassette-shaped constructional units in a rotary printing machine |
| 05/16/2002 | WO2001029255A3 Diagnostic test for cephalic pain |
| 05/16/2002 | WO2001007434A3 Indole derivatives and their use as 5ht2a ligands |
| 05/16/2002 | US20020059653 Modulating protein complex formation in cells; obtain sample tissue, incubate with acetylcholine esterase, expose to modulator, monitor sample for complex formation |
| 05/16/2002 | US20020058839 Methods and compositions for modulating alpha adrenergic receptor activity |
| 05/16/2002 | US20020058813 Spiro-indolines as Y5 receptor antagonists |
| 05/16/2002 | US20020058809 For therapy of autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis |
| 05/16/2002 | US20020058700 Ion channel modulating agents |
| 05/16/2002 | US20020058699 Administering compound that reduces mitogen-activated protein kinase (MAPK) activity in neurons of the individual for reducing or inhibiting excessive neuronal excitability |
| 05/16/2002 | US20020058689 Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi]indole derivatives |
| 05/16/2002 | US20020058685 Hydantoin derivative compounds, pharmace utical compositions, and methods of using same |
| 05/16/2002 | US20020058681 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 05/16/2002 | US20020058678 For therapy of diseases or pathological conditions involving inflammation such as chronic inflammatory diseases |
| 05/16/2002 | US20020058672 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines |
| 05/16/2002 | US20020058663 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
| 05/16/2002 | US20020058652 Pharmaceutical compositions and methods for use |
| 05/16/2002 | US20020058644 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/16/2002 | US20020058631 Dipeptide derivatives |
| 05/16/2002 | US20020058630 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 05/16/2002 | US20020058627 Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
| 05/16/2002 | US20020058613 Modulating the expression or bioactivity of a bcl family member in a neural cell such that axonal growth occurs. |
| 05/16/2002 | US20020058284 Methods and compositions for treating macrophage-mediated diseases |
| 05/16/2002 | US20020058276 Proteins related to schizophrenia and uses thereof |
| 05/16/2002 | US20020058267 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's disease |
| 05/16/2002 | US20020058062 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism |
| 05/16/2002 | US20020058061 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 05/16/2002 | US20020058058 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 05/16/2002 | US20020058050 Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level |
| 05/16/2002 | US20020058048 Contains a nonionic, amphoteric or cationic surfactant in an amount effective to eliminate or substantially ameliorate burning pain caused by capsaicin. |
| 05/16/2002 | US20020058038 Specific octapeptides, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds and immune effector cells raised in response to presentation of these epitopes. |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/16/2002 | US20020058023 Apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells. |
| 05/16/2002 | US20020058022 Novel compounds |
| 05/16/2002 | US20020058009 Pulmonary delivery in treating disorders of the central nervous system |
| 05/16/2002 | DE10054641A1 Verwendung einer Zubereitung von Cimicifuga racemosa Use of a preparation of Cimicifuga racemosa |
| 05/16/2002 | DE10054279A1 Verwendung von Liganden von Todesrezeptoren oder RIP zur Auslösung des Caspase-unabhängigen Zelltods und Verbindungen zur Inhibition des Caspase-unabhängigen Zelltods Use of ligands of death receptors or RIP to trigger the caspase-independent cell death and compounds for inhibition of the caspase-independent cell death |
| 05/16/2002 | CA2429000A1 Adjuvant combination formulations |
| 05/16/2002 | CA2428241A1 Novel human potassium channel beta subunit |
| 05/16/2002 | CA2428176A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | CA2428161A1 Substances causing differentiation |
| 05/16/2002 | CA2428159A1 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | CA2428055A1 Process for the preparation of latent antithrombin iii |
| 05/16/2002 | CA2427779A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 05/16/2002 | CA2427757A1 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | CA2427283A1 Device and method for the cessation of smoking |
| 05/16/2002 | CA2426037A1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | CA2426030A1 Methods of treating disorders related to apoe |
| 05/16/2002 | CA2425980A1 Foggy |
| 05/16/2002 | CA2425829A1 Proteases |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205478A1 p38MAP KINASE INHIBITORS |
| 05/15/2002 | EP1205191A1 Targeted modification of intracellular compounds |
| 05/15/2002 | EP1205187A1 Remedies for neurogenic pains |
| 05/15/2002 | EP1204754A2 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby |
| 05/15/2002 | EP1204748A2 New g-protein coupled receptor and dna sequences thereof |
| 05/15/2002 | EP1204747A1 G protein-coupled receptor expressed in brain |
| 05/15/2002 | EP1204679A1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 05/15/2002 | EP1204674A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 05/15/2002 | EP1204669A1 Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration |
| 05/15/2002 | EP1204665A2 Chemokine receptor antagonists and methods of use therefor |
| 05/15/2002 | EP1204663A1 Novel spiro compounds |
| 05/15/2002 | EP1204662A1 Azaindoles having serotonin receptor affinity |
| 05/15/2002 | EP1204660A1 Serotonergic benzothiophenes |
| 05/15/2002 | EP1204659A2 Serotonergic benzofurans |
| 05/15/2002 | EP1204658A1 Benzofurylpiperazine serotonin agonists |
| 05/15/2002 | EP1204657A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 05/15/2002 | EP1204656A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204655A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204654A1 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 05/15/2002 | EP1204652A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/15/2002 | EP1204649A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 05/15/2002 | EP1204641A1 4-aminopiperidine derivatives of tetrahydronaphthalene, chromans and thiochromans |
| 05/15/2002 | EP1204626A1 Ether compounds, compositions, and uses thereof |
| 05/15/2002 | EP1204429A2 Sustained release formulation of a peptide |
| 05/15/2002 | EP1204414A2 Use of morphinan derivates as medicines |
| 05/15/2002 | EP1204407A2 Implantable active ingredient depot |
| 05/15/2002 | EP1204406A2 Opioid sustained-released formulation |
| 05/15/2002 | EP1177797A9 Novel use |
| 05/15/2002 | EP1049694B1 Derivatives of benzoxadiazoles, benzothiadiazoles, benzotriazoles and quinoxalines |
| 05/15/2002 | EP1032391B1 Spheroids containing tiagabine, preparation process and pharmaceutical compositions |
| 05/15/2002 | EP0923549B1 Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use |
| 05/15/2002 | EP0778833B1 Endothelin receptor antagonists |
| 05/15/2002 | EP0750509B1 USE OF IL-12 AND IL-12 ANTAGONISTS for the manufacture of a pharmaceutical composition for THE TREATMENT OF AUTOIMMUNE DISEASES |
| 05/15/2002 | CN1349533A Heteroaryl diazabicycloalkanes, their prepn. and use |
| 05/15/2002 | CN1349527A Substituted benzolactam compounds |
| 05/15/2002 | CN1349523A Novel lipoic acid derivatives, their prepn., and pharmaceutical compositions containing them |
| 05/15/2002 | CN1349510A Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 05/15/2002 | CN1349509A Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 05/15/2002 | CN1349506A Heterocyclic compounds having effect of activating nicoting acetylchloine alpha 4 beta 2 receptor |
| 05/15/2002 | CN1349497A Monofluoroalkyl derivatives |
| 05/15/2002 | CN1349496A Caspase inhibitors and the use thereof |
| 05/15/2002 | CN1349485A 糖皮质激素受体调制剂 Glucocorticoid receptor modulators |
| 05/15/2002 | CN1349423A Composition comprising tramadol aterial and a selective cox-2 inhibitor drug |
| 05/15/2002 | CN1349407A Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumponiae infections |
| 05/15/2002 | CN1348956A Substituted diazacycloheptane compound, medicine composite contg. same and the use thereof |